Understanding the impact of risankizumab on keratinocyte-derived IL-23A in a novel organotypic 3D skin model containing IL-23A responsive and IL-17A producing γδ-T-cells

References

• Bugaut H, Aractingi S. Major role of the IL17/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol. 2021;12:621956. doi: 10.3389/fimmu.2021.621956.
   PubMed Web of Science ®Google Scholar
• Schön MP, Erpenbeck L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323. doi: 10.3389/fimmu.2018.01323.
   PubMed Web of Science ®Google Scholar
• Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Sci Rep. 2017;7(1):15631. doi: 10.1038/s41598-017-15892-7.
   PubMedGoogle Scholar
• Sachen KL, Arnold Greving CN, Towne JE. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine. 2022;156:155897. doi: 10.1016/j.cyto.2022.155897.
   PubMed Web of Science ®Google Scholar
• Bridgewood C, Stacey M, Alase A, et al. IL-36gamma has proinflammatory effects on human endothelial cells. Exp Dermatol. 2017;26(5):402–408. doi: 10.1111/exd.13228.
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L. Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int J Mol Sci. 2021;22(9):4344. doi: 10.3390/ijms22094344.
   PubMed Web of Science ®Google Scholar
• Ainscough J, Macleod T, McGonagle D, et al. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ. Proc Natl Acad Sci U S A. 2017;114(13):E2748–E2757.
   PubMed Web of Science ®Google Scholar
• Ngo VL, Abo H, Maxim E, et al. A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage. Proc Natl Acad Sci U S A. 2018;115(22):E5076–E5085.
   PubMed Web of Science ®Google Scholar
• Blair HA. Risankizumab: a review in moderate to severe plaque psoriasis. Drugs. 2020;80(12):1235–1245. doi: 10.1007/s40265-020-01357-1.
   PubMed Web of Science ®Google Scholar
• Heise R, Mey J, Neis MM, et al. Skin retinoid concentrations are modulated by CYP26AI expression restricted to basal keratinocytes in normal human skin and differentiated 3D skin models. J Invest Dermatol. 2006;126(11):2473–2480. doi: 10.1038/sj.jid.5700432.
   PubMed Web of Science ®Google Scholar
• Marquardt Y, Amann PM, Heise R, et al. Characterization of a novel standardized human three-dimensional skin wound healing model using non-sequential fractional ultrapulsed CO2 laser treatments. Lasers Surg Med. 2015;47(3):257–265. doi: 10.1002/lsm.22341.
   PubMed Web of Science ®Google Scholar
• Schmitt L, Marquardt Y, Amann P, et al. Comprehensive molecular characterization of microneedling therapy in a human three-dimensional skin model. PLOS One. 2018;13(9):e0204318. doi: 10.1371/journal.pone.0204318.
   PubMed Web of Science ®Google Scholar
• Huth S, Schmitt L, Marquardt Y, et al. Effects of a ceramide-containing water-in-oil ointment on skin barrier function and allergen penetration in an IL-31 treated 3D model of the disrupted skin barrier. Exp Dermatol. 2018;27(9):1009–1014. doi: 10.1111/exd.13697.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–475. doi: 10.1111/bjd.20818.
   PubMed Web of Science ®Google Scholar
• Gracia-Cazaña T, Bernal-Masferrer L, Morales-Callaghan AM, et al. Risankizumab for the treatment of moderate to severe psoriasis: impact on health-related quality of life and psychological wellbeing. Clin Cosmet Investig Dermatol. 2023;16:221–229. doi: 10.2147/CCID.S296544.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658. doi: 10.1001/jamadermatol.2020.0723.
   PubMed Web of Science ®Google Scholar
• Papotto PH, Ribot JC, Silva-Santos B. IL-17(+) gammadelta T cells as kick-starters of inflammation. Nat Immunol. 2017;18(6):604–611. doi: 10.1038/ni.3726.
   PubMed Web of Science ®Google Scholar
• Bridgewood C, Fearnley GW, Berekmeri A, et al. IL-36gamma Is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis. Front Immunol. 2018;9:200. doi: 10.3389/fimmu.2018.00200.
   PubMed Web of Science ®Google Scholar
• Su Z, Paulsboe S, Wetter J, et al. IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis. Exp Dermatol. 2019;28(2):113–120. doi: 10.1111/exd.13841.
   PubMed Web of Science ®Google Scholar
• Qi C, Wang Y, Li P, et al. Gamma delta T cells and their pathogenic role in psoriasis. Front Immunol. 2021;12:627139. doi: 10.3389/fimmu.2021.627139.
   PubMed Web of Science ®Google Scholar
• Todorović V, McDonald HA, Hoover P, et al. Cytokine induced 3-D organotypic psoriasis skin model demonstrates distinct roles for NF-kappaB and JAK pathways in disease pathophysiology. Exp Dermatol. 2022;31(7):1036–1047. doi: 10.1111/exd.14551.
   PubMed Web of Science ®Google Scholar